Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients
Secondary Hyperparathyroidism
About this trial
This is an interventional treatment trial for Secondary Hyperparathyroidism
Eligibility Criteria
Inclusion Criteria:1. End Stage Renal Failure (ESRF) patients on haemodialysis with iPTH levels more than 9x upper limit normal 2. Patients who has history of active Vitamin D analogue doses limited by hypercalcaemia (>2.54 mmol/L)
Exclusion Criteria:
- Pregnant or breastfeeding or planning to become pregnant
- Life expectancy of 6 months or less
- History of decompensated liver disease
Sites / Locations
- Clinical Research Centre, Penang Hospital
- Penang Hospital
Arms of the Study
Arm 1
Experimental
Cinacalcet with Vitamin D arm
Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.